| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | EVP, R&D and CSO | Common Stock, $0.01 par value | 42,276 | $8,667,426 | $205.02 | 28 Feb 2025 | Direct |
| AbbVie Inc. | EVP, R&D and CSO | Option (Right to buy) | 25,000 | $2,337,500 | $93.5 | 13 Feb 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 28 Feb 2025 | 1 | -$959,083 | 4 | EVP, R&D and CSO | 04 Mar 2025, 17:00 |
| ABBV | AbbVie Inc. | 13 Feb 2025 | 5 | $0 | 4 | EVP, R&D and CSO | 18 Feb 2025, 17:00 |
| ABBV | AbbVie Inc. | 28 Feb 2024 | 1 | -$879,556 | 4 | SVP, CMO, GLOBAL THERAPEUTICS | 01 Mar 2024, 17:50 |
| ABBV | AbbVie Inc. | 15 Feb 2024 | 5 | $0 | 4/A | EVP, R&D and CSO | 07 Feb 2025, 16:00 |
| ABBV | AbbVie Inc. | 14 Dec 2023 | 0 | $0 | 3 | SVP, Global Therapeutics & CMO | 22 Dec 2023, 16:13 |